BioSpace News Archive

Lexicon Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001.

Elevar Therapeutics, Inc. announced its participation plans for the 2023 American Society of Clinical Oncology Annual Meeting in Chicago and the 2023 BIO International Convention in Boston.

Exact Sciences Corp. announced that the company has been certified as a 2023 Great Place To Work® for the fifth consecutive year.

Poseida Therapeutics, Inc. today announced that its virtual Annual Meeting of Stockholders (the “Annual Meeting”) will be held on Thursday, June 15, 2023 at 1:00 p.m. PT.

BIORCHESTRA today announced that Dr. Branden Ryu, Founder, Chairman, and Chief Executive Officer, has accepted an invitation to present the company’s discovery program, brain-specific gene targeted siRNA-BTRiN and non human primate (NHP) study outcomes from its lead program – BMD-001 – at the 2023 Biotechnology Innovation Organization International Convention.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company’s IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL , and virtually.

Ventus Therapeutics announced today that the company’s Head of Platform Technologies, Jason Burch, Ph.D., will give an oral presentation on ReSOLVE™, Ventus’ proprietary drug discovery platform, at the Canadian Chemistry Conference and Exhibition (CSC) 2023, being held on June 4-8, 2023 in Vancouver, British Columbia.

MEI Pharma, Inc. announced that its Board of Directors reviewed and rejected the unsolicited and non-binding proposal received on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of the Company’s clinical assets.

Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline.

LAVA Therapeutics N.V. today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference.